Login to Your Account



Low End $39.6M for Stem Cell Push

Hey Jalousie: IPO Window Still Open, but Pricing ‘Fates’ Vary

By Randy Osborne
Staff Writer

Tuesday, October 1, 2013
The latest to price its initial public offering (IPO), Fate Therapeutics Inc. garnered about $39.6 million, an amount at the low end of its already-dipped target range, selling about 6.6 million shares at $6 each. Shares of San Diego-based Fate (NASDAQ:FATE) closed Tuesday at $6.62, up 10.3 percent.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription